Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Gressens, D. Castanares, J. Jamart, P. Bulpa, E. Installé, P. Evrard (Yvoir, Belgium). Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension. Eur Respir J 2005; 26: Suppl. 49, 3132

Member's Comments

No comment yet.

Related content which might interest you: Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 339-343 Year: 2002 Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Inhaled iloprost improves hemodynamics at exercise in primary and secondary precapillary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Sex and haemodynamics in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 523-530 Year: 2013 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001